Lupin partners with Sandoz to market, commercialize Ranibizumab biosimilar across multiple regions
Lupin will be responsible for manufacturing the product and for regulatory submissions.;
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-08-12 11:51 GMT | Update On 2025-08-12 11:51 GMT
Advertisement
Mumbai: Global Pharma major Lupin Limited has announced that it has partnered with Sandoz Group AG, Switzerland, to market and commercialize Lupin's biosimilar ranibizumab across multiple regions.
Under the terms of the agreement, Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.
Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights.
Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialization of Lupin’s biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.